$MRNA · Moderna, Inc.
Moderna filed an 8-K disclosing a Transitional Services and Retirement Agreement with Chief Legal Officer Shannon Thyme Klinger, dated November 13, 2026. She will continue employment through March 31, 2027, receiving current base salary, benefits, and equity vesting, plus a 2026 bonus tied to corporate performance. Severance totals $1,628,300 (twelve months' salary plus target bonus) paid over twelve months, with COBRA premiums covered through September 30, 2028. She may also receive up to $2,500,000 tied to Arbutus/Genevant litigation and up to $5,500,000 tied to Pfizer/BioNTech litigation.
- Klinger retires March 31, 2027, transitioning duties until then.
- Severance of $1,628,300 equals twelve months' base salary plus target bonus.
- COBRA premiums covered until September 30, 2028.
- Up to $2.5M contingent on Arbutus/Genevant litigation outcome.
- Up to $5.5M contingent on Pfizer/BioNTech litigation outcome.
Extended-hours last trade $222.30, down 0.48% vs regular close and 0.44% vs price at filing — a muted reaction consistent with a routine executive retirement.
A top legal officer exits while Moderna's key mRNA patent disputes remain unresolved, with her payouts directly tied to those outcomes.
_Not applicable._
Departure of a senior legal officer during ongoing high-stakes patent litigation with Arbutus, Genevant, Pfizer, and BioNTech could create transition risk.